摘要
应用BCOPP/CHOP-B交替联合化疗方案,治疗60例中度及高度恶性非何杰金淋巴瘤(NHL),完全缓解率(CR)为60%,3年生存率为56.8%。中度恶性组、体力状况0及1级、临床分期Ⅰ、Ⅱ、Ⅲ期和A组患者3年生存率分别为80.6%、87.1%、63.1%和74.8%,高度恶性组、体力分级≥2级、Ⅳ期、B症状和血清乳酸脱氢酶(LDH)≥3.34μmol·S/L患者预后不良,3年生存率分别为27.5%、7.0%、34.2%、12.8%和22.5%。上述结果表明本化疗方案更适用于治疗较早期(Ⅰ、Ⅱ、Ⅲ期)的中度恶性NHL患者。
patients with intermediate or high grade non-Hodgkin lymphoma (NHL) were treated with BCOPP/CHOP-B regimen, 36 patients(60%)achieved a complete remission(CR)after 6~8cycles of chemotherapy. The overall survival at three years was 56.8%. Three-year survival rates for the patients with intermediate grade subtype,performance status 0 and 1 grade, clinic stage Ⅰ,Ⅱand Ⅲ, and without 'B' symptoms,were 80.6%,87.1%,63.1%and 74.8%respectively. The prognosis was poor with high grade subtype, performance status≥2grade,stage Ⅳ'B' symptoms and LDH≥3. 34μmol·S/L, Three-year survival rate was 27.5%in high grade group,7.0%in performance status≥2 group, 34.2% in stage Ⅳ group, 12.8% in'B' symptom group and 22.5%in LDH≥200U/L group, The results illustrated that the regimen was more satisfactory for the patients with intermediate grade NHL at in each stage(Ⅰ、Ⅱ、Ⅲ).
出处
《北京医学》
CAS
北大核心
1995年第2期65-68,共4页
Beijing Medical Journal